Cargando…
Venetoclax in Previously Treated Waldenström Macroglobulinemia
PURPOSE: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetoclax in WM remains to be clarified. PATIENTS AND METH...
Autores principales: | Castillo, Jorge J., Allan, John N., Siddiqi, Tanya, Advani, Ranjana H., Meid, Kirsten, Leventoff, Carly, White, Timothy P., Flynn, Catherine A., Sarosiek, Shayna, Branagan, Andrew R., Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Patterson, Christopher J., Hunter, Zachary R., Davids, Matthew S., Furman, Richard R., Treon, Steven P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683218/ https://www.ncbi.nlm.nih.gov/pubmed/34793256 http://dx.doi.org/10.1200/JCO.21.01194 |
Ejemplares similares
-
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
por: Gustine, Joshua N., et al.
Publicado: (2021) -
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
por: Castillo, Jorge J., et al.
Publicado: (2022) -
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021) -
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2021) -
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
por: Castillo, Jorge J., et al.
Publicado: (2022)